Lack of investments in drug development, lack of standardisation of clinical trials and the complexity of disease presentations contribute to the current lack of effective, safe and adapted treatments for cutaneous leishmaniasis (CL). One aspect concerns outcomes affecting patients' quality of life (QoL): these are hardly assessed in trials, despite potential functional and/or aesthetic impairment caused by CL, which typically affects disadvantaged and vulnerable people living in rural areas. Here, we describe the approach used to bring perspectives of patients with CL into designing and assessing treatments.This international qualitative study uses interviews with patients to explore their experiences with CL to (1) elicit outcomes and eli...
Background: Cutaneous leishmaniasis (CL), is the most common form of a group of diseases known as le...
Background: The aim of this study was to explore the experiences of patients who suffer from acute c...
OBJECTIVE:To document the sources of heterogeneity in outcomes and shortcomings in trial designs rep...
International audienceINTRODUCTION:Lack of investments in drug development, lack of standardisation ...
BackgroundCutaneous leishmaniasis (CL) is a disease that often affects exposed skin areas and may he...
International audienceBackgroundCutaneous leishmaniasis (CL) is a disease that often affects exposed...
Background: Cutaneous leishmaniasis (CL) is a disease that often affects exposed skin areas and may ...
BACKGROUND:Until now, few studies have evaluated the effect of cutaneous leishmaniasis (CL) on patie...
BackgroundUntil now, few studies have evaluated the effect of cutaneous leishmaniasis (CL) on patien...
Background: The aim of this study was to explore the experiences of patients who suffer from acute c...
Background: The aim of this study was to explore the experiences of patients who suffer from acute c...
Background: The aim of this study was to explore the experiences of patients who suffer from acute c...
Background: The aim of this study was to explore the experiences of patients who suffer from acute c...
Background: The aim of this study was to explore the experiences of patients who suffer from acute c...
Background: Cutaneous leishmaniasis (CL), is the most common form of a group of diseases known as le...
Background: Cutaneous leishmaniasis (CL), is the most common form of a group of diseases known as le...
Background: The aim of this study was to explore the experiences of patients who suffer from acute c...
OBJECTIVE:To document the sources of heterogeneity in outcomes and shortcomings in trial designs rep...
International audienceINTRODUCTION:Lack of investments in drug development, lack of standardisation ...
BackgroundCutaneous leishmaniasis (CL) is a disease that often affects exposed skin areas and may he...
International audienceBackgroundCutaneous leishmaniasis (CL) is a disease that often affects exposed...
Background: Cutaneous leishmaniasis (CL) is a disease that often affects exposed skin areas and may ...
BACKGROUND:Until now, few studies have evaluated the effect of cutaneous leishmaniasis (CL) on patie...
BackgroundUntil now, few studies have evaluated the effect of cutaneous leishmaniasis (CL) on patien...
Background: The aim of this study was to explore the experiences of patients who suffer from acute c...
Background: The aim of this study was to explore the experiences of patients who suffer from acute c...
Background: The aim of this study was to explore the experiences of patients who suffer from acute c...
Background: The aim of this study was to explore the experiences of patients who suffer from acute c...
Background: The aim of this study was to explore the experiences of patients who suffer from acute c...
Background: Cutaneous leishmaniasis (CL), is the most common form of a group of diseases known as le...
Background: Cutaneous leishmaniasis (CL), is the most common form of a group of diseases known as le...
Background: The aim of this study was to explore the experiences of patients who suffer from acute c...
OBJECTIVE:To document the sources of heterogeneity in outcomes and shortcomings in trial designs rep...